To The Moon

Founded in 2011, California-based $Tempest Therapeutics Inc.(TPST)$ deals primarily in developing treatments for cancer patients.

The cancer therapies company surged 4000% during the trading hours after it reported positive results for its TPST-1120 drug candidate in clinical study.

HCC (Hepatocellular Carcinoma) is an aggressive cancer, with over 900,000 people diagnosed worldwide every year. Furthermore, it is projected to become the third leading cause of cancer-related deaths by 2030.

Clinical trial shows significant progress of its drug in treating liver cancer

Tempest conducted the study that sent TPST stock up in conjunction with Swiss healthcare company $Roche Holding Ltd(RHHBY)$ , and its stock is also rising today.

1) Higher objective response rate (ORR) - reduce tumor size or completely disappear

A higher ORR means that a larger proportion of patients in a clinical trial experienced a reduction in tumor size or saw their cancer partially or completely disappear in response to the treatment being tested.

2) Longer progression-free survival time (up 60%)

In the Tempest trial, uHCC patients who received the combination therapy of the three drugs had a median progression-free survival (PFS) of 7 months, compared with PFS of 4.3 months of the control group. 

It means patients' progression-free survival duration increased by more than 60%.

3) Exploring more possibilities in treating other tumors

Tempest is also testing against other types of tumors to measure its effectiveness in combating other cancers.

Tempest announced poison pill plan to prevent unwanted takeover

Tempest announced that its board of directors had adopted a limited-duration stockholder rights plan, which is effective immediately. The plan seeks to protect shareholders from an unwanted takeover. It is also known as a poison pill plan.

This step also explains why penny stock can rise 4000% overnight. The breakthrough means that big giants like $Pfizer(PFE)$ or $Eli Lilly(LLY)$ may acquire the company.